Sucampo Pharmaceuticals Inc. | TalkMarkets | Page 1
No data available
No data available

People who follow this stock (42)

View All

Latest Posts

About This Stock More About This Stock
A Moody's Downgrade Could Punish Mallinckrodt
Article By: Shock Exchange
Monday, January 1, 2018 10:00 PM EDT
MNK's $1.2B acquisition of SCMP will diversity its earnings stream but will likely increase debt by over $800MM. Proforma debt/EBITDA could reach 4.8x - 4.9x. Moody's put MNK's debt under review for a rating downgrade.
In this article: MNK, SCMP
Read
Mallinckrodt: Impact Of $1.2 Billion Sucampo Deal Could Be Ethereal
Article By: Shock Exchange
Thursday, December 28, 2017 4:20 AM EDT
MNK recently acquired SCMP for $1.2 billion. The transaction could help sentiment in the short-term. However, SCMP will not stem MNK's revenue decline and it will likely increase debt by over $800MM.
In this article: MNK, SCMP Also: TKPHF, RDY, CELG, GILD
Read
Sucampo 'Substantially' Undervalued In $18 Per Share Deal, Says Nomura Instinet
Article By: The Fly
Tuesday, December 26, 2017 10:21 PM EDT
The low deal price could create interest from other parties.
In this article: MNK, SCMP
Read
Sucampo Pharmaceuticals, Inc. Stock Climbs On Mallinckrodt PLC Buyout Deal
Article By: ValueWalk
Tuesday, December 26, 2017 11:15 AM EDT
Sucampo Pharmaceuticals, Inc. stock surged in early trading on Tuesday after the company finalized an agreement to sell itself to Mallinckrodt PLC for $2.1 billion. Excluding debt, the acquisition is valued at approximately $840 million.
In this article: SCMP, MNK
Read
Sucampo Pharmaceuticals, Inc. Buying Rare Disease Player "Vtesse" For $200M
Article By: Lorimer Wilson
Monday, April 3, 2017 1:22 PM EDT
Sucampo Pharmaceuticals is buying Vtesse for $200 million. In doing so, Sucampo is picking up a late-stage asset, VTS-270, now in a global pivotal trial, with a readout expected in mid-2018. Sucampo is confidently projecting a market launch in 2019.
In this article: SCMP
Read
All Posts

Latest Tweets for $SCMP

No tweets yet!

PARTNER HEADLINES